{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ruppert AM"],"funding":["Roche","Novartis, France","Institut National Du Cancer, France","AstraZeneca"],"pagination":["100052"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8474404"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1(3)"],"pubmed_abstract":["<h4>Introduction</h4><i>KRAS</i> mutations are detected in 20% to 30% of NSCLC. However, <i>KRAS</i> mutation subtypes may differently influence the outcome of patients with advanced NSCLC.<h4>Methods</h4>In the Biomarkers France study, 4894 <i>KRAS</i> mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the <i>KRAS</i> mutations subtype.<h4>Results</h4>Over 95% of patients with <i>KRAS</i> mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common <i>KRAS</i> mutation subtyp"],"journal":["JTO clinical and research reports"],"pubmed_title":["Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes."],"pmcid":["PMC8474404"],"funding_grant_id":["2011-038"],"pubmed_authors":["Bringuier PP","Debieuvre D","Foucher P","Janicot H","Barlesi F","Westeel V","Ricordel C","Poudenx M","Escande F","Beau-Faller M","Ouafik L","Rouquette I","Lemoine A","Merlio JP","Ruppert AM","Mazieres J","Monnet I","Morin F","Langlais A","Souquet PJ","Wislez M"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes.","description":"<h4>Introduction</h4><i>KRAS</i> mutations are detected in 20% to 30% of NSCLC. However, <i>KRAS</i> mutation subtypes may differently influence the outcome of patients with advanced NSCLC.<h4>Methods</h4>In the Biomarkers France study, 4894 <i>KRAS</i> mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the <i>KRAS</i> mutations subtype.<h4>Results</h4>Over 95% of patients with <i>KRAS</i> mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common <i>KRAS</i> mutation subtyp","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-06-01T00:32:05.837Z","creation":"2025-06-01T00:32:05.837Z"},"accession":"S-EPMC8474404","cross_references":{"pubmed":["34589947"],"doi":["10.1016/j.jtocrr.2020.100052"]}}